Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.
Identifieur interne : 003438 ( PubMed/Corpus ); précédent : 003437; suivant : 003439Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.
Auteurs : Hila Haskelberg ; Patrick W G. Mallon ; Jennifer Hoy ; Janaki Amin ; Cecilia Moore ; Praphan Phanuphak ; Samuel Ferret ; Waldo H. Belloso ; Mark A. Boyd ; David A. Cooper ; Sean EmerySource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2014.
English descriptors
- KwdEn :
- Absorptiometry, Photon, Adult, Anti-HIV Agents (administration & dosage), Anti-HIV Agents (adverse effects), Bone Density (drug effects), Female, Humans, Longitudinal Studies, Lopinavir (administration & dosage), Lopinavir (adverse effects), Male, Pelvic Bones (diagnostic imaging), Pyrrolidinones (administration & dosage), Pyrrolidinones (adverse effects), Raltegravir Potassium, Ritonavir (administration & dosage), Ritonavir (adverse effects), Spine (diagnostic imaging).
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Lopinavir, Pyrrolidinones, Ritonavir.
- chemical , adverse effects : Anti-HIV Agents, Lopinavir, Pyrrolidinones, Ritonavir.
- diagnostic imaging : Pelvic Bones, Spine.
- drug effects : Bone Density.
- Absorptiometry, Photon, Adult, Female, Humans, Longitudinal Studies, Male, Raltegravir Potassium.
Abstract
To compare bone mineral density (BMD) changes over 96 weeks in adults virologically failing standard first-line therapy, randomized to raltegravir plus lopinavir/ritonavir (RAL + LPV/r) or conventional 2-3 nucleoside/nucleotide reverse transcriptase inhibitors [N(t)RTIs] + LPV/r second-line therapy.
DOI: 10.1097/QAI.0000000000000288
PubMed: 25072617
Links to Exploration step
pubmed:25072617Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.</title><author><name sortKey="Haskelberg, Hila" sort="Haskelberg, Hila" uniqKey="Haskelberg H" first="Hila" last="Haskelberg">Hila Haskelberg</name><affiliation><nlm:affiliation>*The Kirby Institute, University of New South Wales, Sydney, Australia; †UCD School of Medicine and Medical Science, Dublin, Ireland; ‡The Alfred Hospital, Melbourne, Australia; §Thai Red Cross AIDS Research Center, Bangkok, Thailand; ‖Hopital Saint-Louis, Paris, France; and ¶CICAL, Buenos Aires, Argentina.</nlm:affiliation></affiliation></author><author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name></author><author><name sortKey="Hoy, Jennifer" sort="Hoy, Jennifer" uniqKey="Hoy J" first="Jennifer" last="Hoy">Jennifer Hoy</name></author><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name></author><author><name sortKey="Moore, Cecilia" sort="Moore, Cecilia" uniqKey="Moore C" first="Cecilia" last="Moore">Cecilia Moore</name></author><author><name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name></author><author><name sortKey="Ferret, Samuel" sort="Ferret, Samuel" uniqKey="Ferret S" first="Samuel" last="Ferret">Samuel Ferret</name></author><author><name sortKey="Belloso, Waldo H" sort="Belloso, Waldo H" uniqKey="Belloso W" first="Waldo H" last="Belloso">Waldo H. Belloso</name></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25072617</idno><idno type="pmid">25072617</idno><idno type="doi">10.1097/QAI.0000000000000288</idno><idno type="wicri:Area/PubMed/Corpus">003438</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003438</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.</title><author><name sortKey="Haskelberg, Hila" sort="Haskelberg, Hila" uniqKey="Haskelberg H" first="Hila" last="Haskelberg">Hila Haskelberg</name><affiliation><nlm:affiliation>*The Kirby Institute, University of New South Wales, Sydney, Australia; †UCD School of Medicine and Medical Science, Dublin, Ireland; ‡The Alfred Hospital, Melbourne, Australia; §Thai Red Cross AIDS Research Center, Bangkok, Thailand; ‖Hopital Saint-Louis, Paris, France; and ¶CICAL, Buenos Aires, Argentina.</nlm:affiliation></affiliation></author><author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name></author><author><name sortKey="Hoy, Jennifer" sort="Hoy, Jennifer" uniqKey="Hoy J" first="Jennifer" last="Hoy">Jennifer Hoy</name></author><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name></author><author><name sortKey="Moore, Cecilia" sort="Moore, Cecilia" uniqKey="Moore C" first="Cecilia" last="Moore">Cecilia Moore</name></author><author><name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name></author><author><name sortKey="Ferret, Samuel" sort="Ferret, Samuel" uniqKey="Ferret S" first="Samuel" last="Ferret">Samuel Ferret</name></author><author><name sortKey="Belloso, Waldo H" sort="Belloso, Waldo H" uniqKey="Belloso W" first="Waldo H" last="Belloso">Waldo H. Belloso</name></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absorptiometry, Photon</term><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Anti-HIV Agents (adverse effects)</term><term>Bone Density (drug effects)</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Lopinavir (administration & dosage)</term><term>Lopinavir (adverse effects)</term><term>Male</term><term>Pelvic Bones (diagnostic imaging)</term><term>Pyrrolidinones (administration & dosage)</term><term>Pyrrolidinones (adverse effects)</term><term>Raltegravir Potassium</term><term>Ritonavir (administration & dosage)</term><term>Ritonavir (adverse effects)</term><term>Spine (diagnostic imaging)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Lopinavir</term><term>Pyrrolidinones</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term><term>Lopinavir</term><term>Pyrrolidinones</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Pelvic Bones</term><term>Spine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bone Density</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Absorptiometry, Photon</term><term>Adult</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Raltegravir Potassium</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To compare bone mineral density (BMD) changes over 96 weeks in adults virologically failing standard first-line therapy, randomized to raltegravir plus lopinavir/ritonavir (RAL + LPV/r) or conventional 2-3 nucleoside/nucleotide reverse transcriptase inhibitors [N(t)RTIs] + LPV/r second-line therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25072617</PMID><DateCreated><Year>2014</Year><Month>09</Month><Day>12</Day></DateCreated><DateCompleted><Year>2015</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7884</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of acquired immune deficiency syndromes (1999)</Title><ISOAbbreviation>J. Acquir. Immune Defic. Syndr.</ISOAbbreviation></Journal><ArticleTitle>Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.</ArticleTitle><Pagination><MedlinePgn>161-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAI.0000000000000288</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare bone mineral density (BMD) changes over 96 weeks in adults virologically failing standard first-line therapy, randomized to raltegravir plus lopinavir/ritonavir (RAL + LPV/r) or conventional 2-3 nucleoside/nucleotide reverse transcriptase inhibitors [N(t)RTIs] + LPV/r second-line therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants underwent dual-energy x-ray absorptiometry at baseline and weeks 48 and 96 to measure total hip and lumbar spine BMD. Analyses were adjusted for gender, body mass index, and smoking. Linear regression was used to compare between-group differences, logistic regression for low BMD (hip or spine Z-score ≤ -2) incidence, and multivariate linear regression to determine predictors of BMD change. This work represents the extension and final results of the previously published initial 48 weeks of the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The population included 210 adults from 5 middle-income countries: 52% females, 52% Asians, 43% Africans, mean age, 39 years (SD, 8 years). In the 2-3 N(t)RTI group (vs. RAL), BMD reduction was greater at the spine (mean change, -4.9% vs. -3.5%; adjusted difference, -1.9%; 95% confidence interval: -3.3 to -0.5%, P = 0.009) and hip (-4.1% vs. -2.2%; -1.9%; -3.4 to -0.4; P = 0.012). BMD decrease was greatest at 48 weeks with stabilization to week 96. Overall, low BMD occurred in 15 participants (7.9%), with no between-group differences. Independent predictors for bone loss included lower body mass index (regression coefficient: hip, -0.18% and spine, -0.26% per 1 kg/m), longer tenofovir exposure (hip, -0.74% and spine, -1.0% per year), greater change in CD4 to week 12 (hip, -5.11% per 10-fold higher), and higher baseline HIV-RNA (spine, -0.7% per 10-fold higher).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Over 96 weeks, there was greater BMD decrease with 2-3 N(t)RTI + LPV/r compared with RAL + LPV/r; the relative decrease at the spine was greater than the hip. BMD decreases with second-line antiretroviral therapy largely occurred in the first 48 weeks with stabilization, but no recovery thereafter.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haskelberg</LastName><ForeName>Hila</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>*The Kirby Institute, University of New South Wales, Sydney, Australia; †UCD School of Medicine and Medical Science, Dublin, Ireland; ‡The Alfred Hospital, Melbourne, Australia; §Thai Red Cross AIDS Research Center, Bangkok, Thailand; ‖Hopital Saint-Louis, Paris, France; and ¶CICAL, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallon</LastName><ForeName>Patrick W G</ForeName><Initials>PW</Initials></Author><Author ValidYN="Y"><LastName>Hoy</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Janaki</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Phanuphak</LastName><ForeName>Praphan</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ferret</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Belloso</LastName><ForeName>Waldo H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Emery</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Acquir Immune Defic Syndr</MedlineTA><NlmUniqueID>100892005</NlmUniqueID><ISSNLinking>1525-4135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011760">Pyrrolidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>43Y000U234</RegistryNumber><NameOfSubstance UI="D000068898">Raltegravir Potassium</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015502" MajorTopicYN="N">Absorptiometry, Photon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015519" MajorTopicYN="N">Bone Density</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010384" MajorTopicYN="N">Pelvic Bones</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011760" MajorTopicYN="N">Pyrrolidinones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068898" MajorTopicYN="N">Raltegravir Potassium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013131" MajorTopicYN="N">Spine</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25072617</ArticleId><ArticleId IdType="doi">10.1097/QAI.0000000000000288</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003438 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003438 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25072617
|texte= Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25072617" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |